40 related articles for article (PubMed ID: 16956348)
1. ASXL1 mutation is a novel risk factor for bleeding in Philadelphia-negative myeloproliferative neoplasms.
Awada H; Bhatta M; Yu H; Ji W; Hou S; Cronin T; Ba Aqeel S; Roy AM; Faisal MS; Kouides P; Mascarenhas J; Griffiths EA; Elshoury A
Leukemia; 2024 Jan; 38(1):210-214. PubMed ID: 37919607
[No Abstract] [Full Text] [Related]
2. Be aware of the X:
Ramil G; Pratcorona M; Nomdedéu JF
Haematologica; 2024 Jun; 109(6):1646-1647. PubMed ID: 38328862
[No Abstract] [Full Text] [Related]
3. Mutations of N-RAS, FLT3 and p53 genes are not involved in the development of acute leukemia transformed from myeloproliferative diseases with JAK2 mutation.
Suzuki M; Abe A; Kiyoi H; Murata M; Ito Y; Shimada K; Morishita Y; Kinoshita T; Naoe T
Leukemia; 2006 Jun; 20(6):1168-9. PubMed ID: 16557239
[No Abstract] [Full Text] [Related]
4. JAK2 V617F mutation, PRV-1 overexpression and endogenous erythroid colony formation show different coexpression patterns among Ph-negative chronic myeloproliferative disorders.
Bellosillo B; Besses C; Florensa L; Solé F; Serrano S
Leukemia; 2006 Apr; 20(4):736-7. PubMed ID: 16453004
[No Abstract] [Full Text] [Related]
5. Diagnostic assays for the JAK2 V617F mutation in chronic myeloproliferative disorders.
Greiner TC
Am J Clin Pathol; 2006 May; 125(5):651-3. PubMed ID: 16707363
[No Abstract] [Full Text] [Related]
6. JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders.
Rossi D; Deambrogi C; Capello D; Cerri M; Lunghi M; Parvis G; Saglio G; Gaidano G; Cilloni D
Br J Haematol; 2006 Oct; 135(2):267-8. PubMed ID: 16956348
[No Abstract] [Full Text] [Related]
7. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
[TBL] [Abstract][Full Text] [Related]
8. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
9. JAK2 V617F: a single mutation in the myeloproliferative group of disorders.
McLornan D; Percy M; McMullin MF
Ulster Med J; 2006 May; 75(2):112-9. PubMed ID: 16755940
[No Abstract] [Full Text] [Related]
10. [A recurrent mutation of the JAK2 gene in chronic myeloproliferative disorders].
Berger R
Pathol Biol (Paris); 2006 May; 54(4):182-4. PubMed ID: 16084028
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
